Trial record 1 of 13 for:
TUDCA | ALS
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS (TUDCA-ALS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03800524 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 11, 2019
Last Update Posted : July 10, 2023
|
Sponsor:
Humanitas Mirasole SpA
Collaborators:
University of Ulm
University of Sheffield
University Hospital, Tours
KU Leuven
UMC Utrecht
University of Dublin, Trinity College
Bruschettini S.r.l.
Istituto Superiore di Sanità
Motor Neurone Disease Association
European Commission
Information provided by (Responsible Party):
Humanitas Mirasole SpA
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | Drug: Tauroursodeoxycholic Acid Drug: Placebo | Phase 3 |
Enrolled patients will be randomized to one of two treatment arms: TUDCA or identical placebo by oral route. The randomization will be performed in a ratio one to one for the two arms.
TUDCA will be administered orally at the dose of 1 g twice daily (2 g daily) for 18 months. Patients will be taking also riluzole at the dose of 50 mg twice daily (100 mg daily).
Patient randomization will take place after a screening (lead-in) period of 12 weeks (3 months) with 3 assessments at 6-week intervals. Clinical assessments during the trial phase will be performed every three months. This will allow measuring the progression rate before and after starting treatment (either active or placebo).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 337 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) |
| Actual Study Start Date : | February 22, 2019 |
| Estimated Primary Completion Date : | December 31, 2023 |
| Estimated Study Completion Date : | December 31, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Amyotrophic lateral sclerosis
MedlinePlus related topics:
Amyotrophic Lateral Sclerosis
Drug Information
available for:
Taurursodiol
| Arm | Intervention/treatment |
|---|---|
Experimental: Tauroursodeoxycholic acid (TUDCA)
|
Drug: Tauroursodeoxycholic Acid
Other Names:
|
Placebo Comparator: Reference therapy
|
Drug: Placebo
|
Primary Outcome Measures :
- Number of responder patients [ Time Frame: 18 months ]Identification of the responder patients defined as those showing an improvement of at least 20% in the ALSFRS-R slope
Secondary Outcome Measures :
- Survival time [ Time Frame: 18 months ]Survival time measured by death or respiratory insufficiency
- ALS disease functional rating scale - revised version (ALSFRS-R) [ Time Frame: 18 months ]Difference in change from baseline in ALSFRS-R. Each task of the scale is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score ranging from 0 = worst to 48 = best.
- ALS Assessment Questionnaire-40 (ALSAQ-40) [ Time Frame: 18 months ]Difference in change from baseline in ALSAQ-40. The instrument contains 40 statements that measure five dimensions of health state: Physical Mobility (10 statements), Activities of Daily Living and Independence (10 statements), Eating and Drinking (5 statements), Communication (5 statements), Emotional Functioning (10 statements). The patient must indicate how often (Never, Rarely, Sometimes, Often, or Always) the statement have been true. Dimension scores are coded on a likert scale, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).
- Forced Vital Capacity [ Time Frame: 18 months ]Difference in change from baseline in Forced Vital Capacity
- EuroQol 5-Dimension-5 Levels (EQ-5D-5L) scale [ Time Frame: 18 months ]Difference in change from baseline in EQ-5D-5L scale. The EQ-5D-5L descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels: 1.no problems, 2.slight problems, 3.moderate problems, 4.severe problems, 5.extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the patient health state. Numbers 1-5 have no arithmetic properties and should not be used as a cardinal score.
- Medical Research Council (MRC) scale [ Time Frame: 18 months ]Difference in change from baseline in muscle force assessed by the MRC scale. The scale rates muscle strength of 6 muscles (3 at the upper and 3 at the lower limbs), bilaterally. Each muscle is graded from 0 = no movement, to 5 = normal strength, giving a total sum-score that ranges from 0 (total paralysis) to 60 (normal strength).
- Neurofilaments levels [ Time Frame: 18 months ]Effect of TUDCA on Neurofilament levels in comparison to placebo
- MMP-9 levels [ Time Frame: 18 months ]Effect of TUDCA on MMP-9 expression in comparison to placebo
- Long-term safety and tolerability [ Time Frame: 18 months ]assessed through adverse reaction, concomitant treatment, physical examination, vital signs and routine haematology and biochemistry analyses
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria at screening visit (month -3)
- Disease duration ≤ 18 months at screening visit (month -3)
- Able to perform reproducible pulmonary function tests at screening visit (month -3)
- Forced vital capacity or slow vital capacity ≥70% of normal at screening visit (month -3)
- Stable on riluzole treatment for 3 months in the lead-in period
- Signed informed consent at screening visit (month -3)
Exclusion Criteria:
- Treatment with edaravone
- Other causes of neuromuscular weakness
- Presence of other neurodegenerative diseases
- Significant cognitive impairment, clinical dementia or psychiatric illness
- Severe cardiac or pulmonary disease
- Other diseases precluding functional assessments
- Other life-threatening diseases
- Any use of non-invasive ventilation (e.g. continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation
- Gastrointestinal disorder that is likely to impair absorption of study drug from the gastrointestinal tract
- Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is longer, prior to dosing
- Any clinically significant laboratory abnormality
- Other concurrent investigational medications
- Active peptic ulcer
- Previous surgery or infections of small intestine
- Patients unable to easily swallow the treatment pills
- Acute inflammation of the gallbladder or bile ducts
- Occurrence of frequent biliary colic, biliary infections, severe pancreatic abnormalities
- Bile duct obstruction, calcified X-ray opaque gallstones and reduced mobility of the gallbladder
- Subjects who weigh 88 lbs (40 kg) or less
- Aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal
- Creatinine clearance 50 ml/min or less
- Any clinically significant neurological, haematological, autoimmune, endocrine, cardiovascular, neoplastic, renal, gastrointestinal, or other disorder that, in the Investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of study results
- Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive TUDCA or that the subject is unable or unlikely to comply with the dosing schedule or study evaluations
- The patient of reproductive potential is sexually active and is not willing to use highly effective contraception during the study and up to 90 days after the day of last dose
- The patient is pregnant or breast feeding
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03800524
Locations
Show 25 study locations
Sponsors and Collaborators
Humanitas Mirasole SpA
University of Ulm
University of Sheffield
University Hospital, Tours
KU Leuven
UMC Utrecht
University of Dublin, Trinity College
Bruschettini S.r.l.
Istituto Superiore di Sanità
Motor Neurone Disease Association
European Commission
Investigators
| Study Chair: | Alberto Albanese, MD | Humanitas Mirasole SpA |
Additional Information:
Publications:
Publications:
| Responsible Party: | Humanitas Mirasole SpA |
| ClinicalTrials.gov Identifier: | NCT03800524 |
| Other Study ID Numbers: |
H2020/755094/2017/IT-01 2018-002722-22 ( EudraCT Number ) 755094 ( Other Grant/Funding Number: European Commission ) |
| First Posted: | January 11, 2019 Key Record Dates |
| Last Update Posted: | July 10, 2023 |
| Last Verified: | July 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Once the dataset has been analysed, a complete, cleaned, anonymized copy of the final data used in conducting the final analyses will be made available to be used in further studies by the research partners or by other research groups and clinicians. To prevent misuse and misinterpretation, relevant study metadata (such as the study protocol, case report forms, documentation providing information about the methodology and procedures used to collect the data, definition of variables and statistical code) will be shared in a data repository with a stable URL. Patient anonymity and legal compliance will be assured throughout all the steps of data transfer. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
| Time Frame: | Three months after the data-entry process and final data curation |
| Access Criteria: | Data will be made available only to qualified designated persons (methodologists, biostatisticians) from other academic institutions, on request. User registration will be required in order to access files. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Ursodoxicoltaurine Motor Neuron Disease Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases Spinal Cord Diseases |
Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Antiviral Agents Anti-Infective Agents Cholagogues and Choleretics Gastrointestinal Agents |